Advanced Enzyme Technologies 将来の成長
Future 基準チェック /26
Advanced Enzyme Technologies利益と収益がそれぞれ年間10%と12.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.2% 10.2%なると予測されています。
主要情報
10.0%
収益成長率
10.16%
EPS成長率
| Chemicals 収益成長 | 19.5% |
| 収益成長率 | 12.3% |
| 将来の株主資本利益率 | 12.20% |
| アナリストカバレッジ | Low |
| 最終更新日 | 05 Feb 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.ナラティブの更新 • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.ナラティブの更新 • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.ナラティブの更新 • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.ナラティブの更新 • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.ナラティブの更新 • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブの更新 • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).分析記事 • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...新しいナラティブ • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.分析記事 • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...分析記事 • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...分析記事 • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...分析記事 • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...分析記事 • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...分析記事 • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...分析記事 • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...分析記事 • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...分析記事 • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...分析記事 • Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...分析記事 • Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2028 | 9,970 | 2,053 | 733 | 1,678 | 1 |
| 3/31/2027 | 8,535 | 1,729 | 876 | 1,441 | 1 |
| 3/31/2026 | 7,806 | 1,687 | 1,044 | 1,568 | N/A |
| 12/31/2025 | 7,096 | 1,522 | N/A | N/A | N/A |
| 9/30/2025 | 7,067 | 1,474 | 1,323 | 1,643 | N/A |
| 6/30/2025 | 6,683 | 1,369 | N/A | N/A | N/A |
| 3/31/2025 | 6,369 | 1,311 | 1,077 | 1,425 | N/A |
| 12/31/2024 | 6,275 | 1,329 | N/A | N/A | N/A |
| 9/30/2024 | 6,194 | 1,371 | 904 | 1,422 | N/A |
| 6/30/2024 | 6,311 | 1,386 | N/A | N/A | N/A |
| 3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
| 12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
| 9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
| 6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
| 3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
| 12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
| 9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
| 6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
| 3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
| 12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
| 9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
| 6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
| 3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
| 12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
| 9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
| 6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
| 3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
| 12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
| 9/30/2019 | 4,366 | 1,210 | N/A | 1,276 | N/A |
| 6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
| 3/31/2019 | 4,220 | 1,111 | N/A | 1,286 | N/A |
| 12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
| 9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
| 6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
| 3/31/2018 | 3,918 | 901 | N/A | 1,160 | N/A |
| 12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
| 9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
| 6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
| 3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
| 12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
| 9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
| 6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
| 3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ADVENZYMESの予測収益成長率 (年間10% ) は 貯蓄率 ( 6.9% ) を上回っています。
収益対市場: ADVENZYMESの収益 ( 10% ) Indian市場 ( 16.3% ) よりも低い成長が予測されています。
高成長収益: ADVENZYMESの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: ADVENZYMESの収益 ( 12.3% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。
高い収益成長: ADVENZYMESの収益 ( 12.3% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ADVENZYMESの 自己資本利益率 は、3年後には低くなると予測されています ( 12.2 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 07:22 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Advanced Enzyme Technologies Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |